CORONA REMEDIES LIMITED Share Price

NSE: CORONA

₹ 2,105.40

+₹75.70 (3.73%)

Last updated 24 Jul, 2026, 15:29 IST

CORONA REMEDIES LIMITED Share Price Today

As of 25 Jul 2026, CORONA REMEDIES LIMITED share price is ₹2,105.40. The stock opened at ₹2,032.00, compared to its previous close of ₹2,029.70. During today's trading session, CORONA REMEDIES LIMITED share price moved in the range of ₹2,032.00 to ₹2,120.90, with an average price of ₹2,076.45 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,336.60 and a high of ₹2,128.40. On the performance front, CORONA REMEDIES LIMITED share price has increased by 50.41% over the last six months and is up 46.90% on a year-on-year basis.

₹2,032.00

3.73% up today

₹2,120.90

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 21.10% YoY

Latest Earning

Net Profit TrendUp by 9.84% QoQ

Latest Earning

Revenue TrendUp by 3.64% QoQ

Stock Performance

OutperformingBeat Nifty by 5.81 % in last 1 month

Shareholding Pattern

DIIDII decreased stake by 40.62%

Shareholding Pattern

FIIFII increased stake by 61.53%

CORONA REMEDIES LIMITED Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹7,65,990+₹2,65,990 (+53.20%)

3 Year

₹7,60,127+₹2,60,127 (+52.03%)

5 Year

₹7,60,127+₹2,60,127 (+52.03%)

₹1,623.80₹2,435.60

Circuit Low

Circuit High

₹1,336.60₹2,128.40

52-Week Low

52-Week High

Circuit

₹1,623.80

₹2,435.60

52-week

₹1,336.60

₹2,128.40

Mkt Cap Cr

12,399.60

P/E

51.41

P/B

12.74

ROE

27.36%

D/E

0.19

ROCE

28.95%

Div. Yield

0.64%

EPS(TTM)

30.22

Turnover

1.66

EV/EBITDA

33.79

Net Margin

13.17%

Op. Margin

20.31%

ROA

18.93%

Quick Ratio

0.62

Curr. Ratio

1.10

Mkt Cap Cr

12,399.60

P/E

51.41

P/B

12.74

ROE

27.36%

D/E

0.19

ROCE

28.95%

Div. Yield

0.64%

EPS(TTM)

30.22

Turnover

1.66

EV/EBITDA

33.79

Net Margin

13.17%

Op. Margin

20.31%

ROA

18.93%

Quick Ratio

0.62

Curr. Ratio

1.10

Based on fundamentals, this stock's

Performance

Excellent

Corona Remedies outperforming all market indices

Valuation

Overvalued

Corona Remedies appears overvalued compared to its peers

Earnings

Excellent

Corona Remedies revenue, operating profit and net profit are growing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,68,842.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.55	3.27	11.27%	0.00	14.95%	423.36	0.93%	0.44	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,05,607.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	97,364.90	30.58	2.56	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	60.26	10.10	18.21%	0.45	16.70%	10.19	0.20%	0.97	13.72

CORONA REMEDIES LIMITED Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹1,403.18	₹1,196.42	₹1,014.47	₹884.05
Other Income	₹10.65	₹5.93	₹6.46	₹7.05
Total Revenue	₹1,413.83	₹1,202.35	₹1,020.93	₹891.10
Total Expenses	₹1,154.58	₹1,004.20	₹902.46	₹780.44
Profit Before Tax	₹240.42	₹198.53	₹118.48	₹110.89
Tax	₹55.30	₹49.10	₹27.98	₹25.96
Profit After Tax	₹185.12	₹149.43	₹90.50	₹84.93
EPS - Basic	₹30.27	₹24.43	₹14.80	₹14.57
EPS - Diluted	₹30.27	₹24.43	₹14.80	₹14.57

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹240.42	₹198.53	₹118.48	₹110.89
Income before WC changes	₹284.77	₹250.84	₹165.35	₹133.44
Change in Assets	-₹32.73	-₹51.80	-₹11.87	-₹33.63
Change in Liabilities	₹26.86	₹34.73	₹21.19	₹28.72
Change in WC	-₹5.87	-₹17.07	₹9.32	-₹4.92
Cash flow from Operations	₹229.48	₹190.49	₹156.76	₹102.70
Cash flow from Investing	-₹256.15	-₹83.86	-₹266.64	-₹50.25
Cash flow from Financing	₹25.28	-₹106.57	₹98.55	-₹44.75
Total Cash Flow	-₹1.39	₹0.06	-₹11.34	₹7.71
Cash (Start of the year)	₹3.22	₹3.16	₹14.49	₹6.82
Cash (End of the year)	₹1.83	₹3.22	₹3.16	₹14.49

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹856.83	₹590.99	₹540.66	₹303.54
Current Assets	₹348.31	₹338.87	₹289.92	₹291.49
Total Assets	₹1,205.14	₹929.86	₹830.58	₹595.02
Current Liabilities	₹361.17	₹239.59	₹224.19	₹137.37
Net Current Asset	-₹12.86	₹99.28	₹65.72	₹154.12
Non-Current Liabilities	₹97.11	₹83.93	₹125.98	₹49.13
Equity Capital	₹746.86	₹606.34	₹480.41	₹408.52
Total Equity & Liabilities	₹1,205.14	₹929.86	₹830.58	₹595.02

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹1,403.18	₹1,196.42	₹1,014.47	₹884.05
Other Income	₹10.65	₹5.93	₹6.46	₹7.05
Total Revenue	₹1,413.83	₹1,202.35	₹1,020.93	₹891.10
Total Expenses	₹1,154.58	₹1,004.20	₹902.46	₹780.44
Profit Before Tax	₹240.15	₹198.15	₹118.48	₹110.66
Tax	₹55.30	₹49.10	₹27.98	₹25.96
Profit After Tax	₹184.85	₹149.05	₹90.50	₹84.70
EPS - Basic	₹30.22	₹24.37	₹14.80	₹14.53
EPS - Diluted	₹30.22	₹24.37	₹14.80	₹14.53

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹240.15	₹198.15	₹118.48	₹110.66
Income before WC changes	₹284.77	₹250.84	₹165.35	₹133.44
Change in Assets	-₹32.73	-₹51.80	-₹11.87	-₹33.63
Change in Liabilities	₹26.86	₹34.73	₹21.19	₹28.72
Change in WC	-₹5.87	-₹17.07	₹9.32	-₹4.91
Cash flow from Operations	₹229.48	₹190.49	₹156.76	₹102.70
Cash flow from Investing	-₹256.15	-₹83.86	-₹266.65	-₹50.25
Cash flow from Financing	₹25.28	-₹106.57	₹98.54	-₹44.75
Total Cash Flow	-₹1.39	₹0.06	-₹11.34	₹7.71
Cash (Start of the year)	₹3.22	₹3.16	₹14.49	₹6.82
Cash (End of the year)	₹1.83	₹3.22	₹3.16	₹14.49

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹855.94	₹590.37	₹540.42	₹303.31
Current Assets	₹348.31	₹338.87	₹289.92	₹291.49
Total Assets	₹1,204.25	₹929.24	₹830.34	₹594.80
Current Liabilities	₹361.17	₹239.59	₹224.19	₹137.37
Net Current Asset	-₹12.86	₹99.28	₹65.73	₹154.12
Non-Current Liabilities	₹97.11	₹83.93	₹125.98	₹49.13
Equity Capital	₹745.97	₹605.72	₹480.18	₹408.29
Total Equity & Liabilities	₹1,204.25	₹929.24	₹830.34	₹594.80

* All values are in INR Crore

Qty

Bid

Ask

Qty

2113

100

Bid Total: 0

Ask Total: 100

Buy orders: 0%

Sell orders: 100%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bullish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

58.73

Neutral

ATR (14)

65.42

Neutral

STOCH(9,6)

13.35

Bullish

STOCH RSI (14)

Bullish

ADX(9)

45.65

Bearish

UO(9)

33.95

Neutral

ROC(12)

2.06

Bullish

WillR(14)

-58.65

Neutral

Period

Simple value

Exponential vaue

2054.18

2048.09

10D

2054.33

2042

20D

2018.53

2003.23

50D

1859.42

1892.99

100D

1736.45

1856.82

About CORONA REMEDIES LIMITED

ISIN

INE02ZQ01018

Sector Market Cap

₹ 12,399.6 Cr

Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others.

CORONA REMEDIES LIMITED Financial Highlights

Revenue: CORONA REMEDIES LIMITED reported revenue of ₹1,413.83 crore in FY26 vs ₹1,202.35 crore in FY25. It showed an increase of 17.59% on a yearly basis.
Operating Profit: CORONA REMEDIES LIMITED reported an operating profit of ₹240.42 crore in FY26 vs ₹198.53 crore in FY25. It showed an increase of 21.10% on a year-on-year basis.
Net Profit: CORONA REMEDIES LIMITED reported a net profit of ₹185.12 crore in FY26 vs ₹149.43 crore in FY25. It showed an increase of 23.88% on a yearly basis.

CORONA REMEDIES LIMITED Quarterly Result Highlights

CORONA REMEDIES LIMITED reported revenue of ₹357.20 crore in Mar 2026, compared with ₹344.66 crore in Dec 2025, representing an increase of 3.64% on a quarter-on-quarter (QoQ) basis.
CORONA REMEDIES LIMITED reported an operating profit of ₹54.74 crore in Mar 2026, compared with ₹55.21 crore in Dec 2025, representing a decrease of 0.85% on a quarter-on-quarter (QoQ) basis.
CORONA REMEDIES LIMITED reported a profit of ₹45.33 crore in Mar 2026, compared with ₹41.27 crore in Dec 2025, reflecting an increase of 9.84% on a QoQ basis.
The earnings per share (EPS) of CORONA REMEDIES LIMITED stood at ₹30.27 during Mar 2026.